SCHEMBL12296304

SCHEMBL12296304

Cc1nc2cc(Cl)ccn2c1C(=O)NCc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
LMNA P02545 2/20 0.58
HTT P42858 2/20 0.58
PKM P14618 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.53
HSD17B10 Q99714 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
ALDH1A1 P00352 4/20 0.50
CYP2C9 P11712 3/20 0.49
CYP2C19 P33261 2/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 1/20 0.49
HCRTR1 O43613 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
GAA P10253 1/20 0.49
HPGD P15428 1/20 0.47
CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384872 0.93 KDM4E (0.57) KDM4ESMN1; SMN2LMNAHTTPKM
SCHEMBL19723523 0.92 CYP2C9 (0.57) KDM4ESMN1; SMN2LMNAHTTPKM
SCHEMBL19723668 0.91 LMNA (0.55) KDM4ESMN1; SMN2LMNAHTTPKM
SCHEMBL1768316 0.88 KDM4E (0.60) KDM4ESMN1; SMN2LMNAHTTPKM
SCHEMBL23655634 0.87 LMNA (0.50) KDM4ESMN1; SMN2LMNAHTTPKM
SCHEMBL19723660 0.87 KDM4E (0.72) KDM4ESMN1; SMN2LMNAHTTPKM
SCHEMBL19723529 0.86 SMN1; SMN2 (0.52) KDM4ESMN1; SMN2LMNAHTTPKM
SCHEMBL17876427 0.86 KDM4E (0.58) KDM4ESMN1; SMN2LMNAHTTPKM
SCHEMBL12296305 0.86 KDM4E (0.58) KDM4ESMN1; SMN2LMNAHTTPKM
SCHEMBL19723587 0.85 KMT2A (0.52) KDM4ESMN1; SMN2LMNAHTTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029389-B2 Anti-inflammation compounds INSTITUT PASTEUR KOREA (KR) 2015-05-12 US claimed
US-8865734-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2014-10-21 US claimed
EP-3257854-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME University of Notre Dame du Lac (US) 2017-12-20 EP disclosed
EP-2547678-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2016-03-16 EP disclosed
EP-2547678-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2016-03-16 EP disclosed
US-9029389-B2 Anti-inflammation compounds INSTITUT PASTEUR KOREA (KR) 2015-05-12 US disclosed
US-9029389-B2 Anti-inflammation compounds INSTITUT PASTEUR KOREA (KR) 2015-05-12 US disclosed
US-8865734-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2014-10-21 US disclosed
US-8865734-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2014-10-21 US disclosed
US-20140155387-A1 Anti-Inflammation Compounds QURIENT, CO. LTD. (KR) 2014-06-05 US disclosed
US-20140155387-A1 Anti-Inflammation Compounds QURIENT, CO. LTD. (KR) 2014-06-05 US disclosed
US-20130065884-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2013-03-14 US disclosed
US-20130065884-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2013-03-14 US disclosed
WO-2012143796-A2 ANTI-INFLAMMATION COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2012-10-26 WO disclosed
WO-2011113606-A1 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065884-A1 Anti-Infective Compounds RABGGTB, ELANE, SERPINB1 KDM4E 4439/4885SMN1; SMN2 4839/4885LMNA 4132/4885
US-20140155387-A1 Anti-Inflammation Compounds NR0B1, NR0B2, NR5A2 KDM4E 2886/4885SMN1; SMN2 3238/4885LMNA 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.